Condition

Advance Solid Tumors

ClinicalTrials.gov condition label

Clinical trials2

Recruiting2

Common interventions2

Lead sponsors shown2

Clinical trials

2 shown

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D MutationsNCT07610798 · 2026-06-01

RECRUITING

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid TumorsNCT07229313 · 2025-11-13

RECRUITING

Common interventions

INV-8989DRUG1KIVU-107DRUG1

Leading sponsors

Kivu Bioscience Inc.1Shenzhen Ionova Life Sciences Co., Ltd.1

Trial status mix

RECRUITING2

Phase mix

PHASE12

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.